Prestige BioPharma Limited (950210) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Prestige BioPharma Limited KRW 4,811, price KRW 5,970, upside -19.4%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Prestige BioPharma Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 5,030 KRW – 40,000 KRW · the 5,970 KRW price screens above the 4,811 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Prestige BioPharma in your weekly email
Every Wednesday you see whether Prestige BioPharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore.
Show more
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in immunity. It also develops PBP1510, a first-in-class antibody, which is in phase 1/2a clinical trial for the treatment of pancreatic cancer; PBP1710, a first-in-class antibody that is in preclinical trials for the treatment of solid tumor and fibrosis; and IDC007, a bispecific antibody for the treatment of CRS. In addition, the company is developing IDC005, IDC001, IDC002, IDC003, IDC008, and IDC009 bispecific antibodies; IDC111, a first-in-class antibody; IDC112, first-in-class antibody; IDC113 first-in-class antibody; IDC332, IDC331, IDC333, and IDC334 novel concept antibodies; and IDC441, an ADC antibody for the treatment of solid tumours. Additionally, it offers biosimilars for immunology, endocrinology, oncology, haematology, and dermatology diseases. Further, it develops IDC221, a PAUF-based pancreatic cancer diagnostic solution for the treatment of pancreatic cancers. Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.
Stock analysis
Prestige BioPharma Limited (950210) currently trades at 5,970 KRW, while our model-based Fair Value estimate is 4,811 KRW, implying the stock looks roughly 24.1% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 17,219 KRW per share, and 6 of the 10 models we run sit above the 5,970 KRW price.
Bear case: the Asset-Based group reads lowest at 4,559 KRW, and 4 of the 10 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Prestige BioPharma Limited reported revenue of 14.3B KRW in FY2025 versus 2.1B KRW in FY2019, a compound +37.8%/yr. Reported net income was 22.3B KRW in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 58% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −19%, 950210 screens richer than that median.
Fair Value models
Bear 4,811 KRWFair Value 4,811 KRWBull 4,811 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,976.7%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.8%
’19
’24
’25
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+8.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.2%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−211% → −470%
Compare Prestige BioPharma Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score45 · Above median
Fair Value upside−19% · Above median
Profitability
Return on assets−7% · Above median
Net margin (TTM)156% · Top 25%
Growth and dividend
Revenue growth−85% · Bottom 25%
Balance sheet
Debt / equity0.08× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Prestige BioPharma Limited (950210) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 4,811 KRW versus a price of 5,970 KRW, about −19% upside (overvalued).
What is the fair value of 950210?
Our model-based fair value for Prestige BioPharma Limited is 4,811 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 5,970 KRW.
What is the quality score of 950210?
Prestige BioPharma Limited has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Prestige BioPharma Limited (950210)?
Our model-based price target is the fair value of 4,811 KRW (as of Sep 24, 2026) from 10 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Prestige BioPharma Limited stock forecast for 2026?
Our models put fair value at 4,811 KRW, about −19% upside versus a price of 5,970 KRW (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Prestige BioPharma Limited (950210)?
Prestige BioPharma Limited reported trailing-twelve-month revenue of about 16.2B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Prestige BioPharma Limited (950210)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Prestige BioPharma Limited it is 4,811 KRW per share (as of Sep 24, 2026), against a price of 5,970 KRW. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Prestige BioPharma Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 950210 trades above its calculated fair value: price 5,970 KRW, fair value 4,811 KRW, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 950210?
No. The price is what the market pays today (5,970 KRW); the fair value is what the company's own numbers justify (4,811 KRW). For Prestige BioPharma Limited the two are 1,159 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Prestige BioPharma Limited worth?
The market values Prestige BioPharma Limited at about 359B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 5,970 KRW; our models calculate a fair value of 4,811 KRW per share.
How solid is the balance sheet of Prestige BioPharma Limited (950210)?
Balance-sheet figures for Prestige BioPharma Limited (as of Sep 24, 2026): return on equity −14.5%, debt of 0.08 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 950210 from its 52-week high?
Prestige BioPharma Limited trades at 5,970 KRW, about 58% below its 52-week high of 14,380 KRW and 19% above the low of 5,030 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 4,811 KRW is for.
Which stocks are comparable to Prestige BioPharma Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Prestige BioPharma Limited stock attractive at the current price?
The data as of Sep 24, 2026: price 5,970 KRW, calculated fair value 4,811 KRW (−19%), Quality Score 42/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 950210 calculated?
We run Prestige BioPharma Limited through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4,811 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Prestige BioPharma Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Prestige BioPharma Limited (950210)?
The closing price on Sep 23, 2026 was 5,970 KRW. Our model-based fair value is 4,811 KRW, about −19% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Prestige BioPharma Limited right now?
The price sits above even our optimistic bull case (4,811 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Prestige BioPharma Limited
How large is the market capitalisation of Prestige BioPharma Limited (950210)?
The market capitalisation of Prestige BioPharma Limited is 359B KRW (≈ $264M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Prestige BioPharma Limited (950210)?
The price-to-sales ratio of Prestige BioPharma Limited is 18.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Prestige BioPharma Limited (950210)?
The return on equity (ROE) of Prestige BioPharma Limited is −14.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Prestige BioPharma Limited (950210)?
On an EBIT basis the return on assets of Prestige BioPharma Limited is −8.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Prestige BioPharma Limited (950210)?
The operating margin of Prestige BioPharma Limited is −5,175% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Prestige BioPharma Limited (950210)?
Revenue at Prestige BioPharma Limited is growing −84.8% versus a year earlier (3y avg +89.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Prestige BioPharma Limited (950210) generate?
The free cash flow of Prestige BioPharma Limited is −95.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Prestige BioPharma Limited (950210) carry?
The net debt of Prestige BioPharma Limited is 28.7B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Prestige BioPharma Limited in the live analysis
One click puts Prestige BioPharma Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
